Showing 4701-4710 of 7385 results for "".
- Baby Skincare Data at American Academy of Pediatricshttps://practicaldermatology.com/news/baby-skincare-data-american-academy-pediatrics/2468324/Kenvue Inc. will present new data demonstrating effective sleep and skin moisturization strategies for babies during the American Academy of Pediatrics (AAP) National Conference & Exhibition, set for September 27 through October 1 in Orlando, Florida. In addition to findings supporting
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Almirall to Present New Drug Data at EADVhttps://practicaldermatology.com/news/almirall-present-new-drug-data-eadv/2468258/Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Derm
- Bio-Oil Announces Scholarships for Nursing Studentshttps://practicaldermatology.com/news/bio-oil-announces-scholarships-nursing-students/2468246/Ten nursing students pursuing labor and delivery careers will receive scholarships as part of Bio-Oil’s Labor of Love campaign, the company announced. Bio-Oil, maker of Bio-Oil Skincare Oils for new mothers, is partnering with the American Association of Colleges of Nursing to provide the
- INTEGUMENT Trials: Once-Daily Roflumilast Cream Reduces AD Symptomshttps://practicaldermatology.com/news/integument-trials-once-daily-roflumilast-cream-reduces-ad-symptoms/2468245/Roflumilast cream, 0.15%, significantly improved symptoms of mild to moderate atopic dermatitis (AD) in two phase 3 clinical trials. Researchers for the INTEGUMENT-1 and INTEGUMENT-2, publishing their results in JAMA Dermatology, evaluated the efficacy and safety of roflumilast cr
- NJ Legislator Pushes to Allow Sunscreen in Schoolshttps://practicaldermatology.com/news/nj-legislator-pushes-allow-sunscreen-schools/2468244/A new bill referred to New Jersey’s Assembly Education Committee would make the Garden State the 29th to pass legislation allowing direct access to sunscreen in schools, according to Insider NJ. Sunscreen is classified by the US Food and Drug Administration (FDA) as an over-the-counter dru
- Study Links Psoriasis to NMSC in Womenhttps://practicaldermatology.com/news/study-links-psoriasis-nmsc-women/2468243/Psoriasis was associated with a higher risk of nonmelanoma skin cancer in women in a new study published in Nature Communications. “An observational and genetic investigation into the association between psoriasis and risk of malignancy” found higher risks of a total of 16 types of cancer